Allergists Respond To FDA Committee Recommendation On Asthma Medication, Encourage Patients With Questions To Contact Physicians The nation's allergists urged a Joint FDA Advisory Committee today to continue to make long-acting beta-2 agonists available for the treatment of moderate-to-severe asthma in appropriate patients.
Source: www.medicalnewstoday.comMonogram Announces Presentation Of Clinical Data For The HERmark™ Breast Cancer Assay At The CTRC-AACR San Antonio Breast Cancer Symposium Monogram Biosciences, Inc. (Nasdaq:MGRM) announced that new results from a study of the predictive power of its HERmark™ Breast Cancer Assay were presented at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
Source: www.medicalnewstoday.comSARcode Announces Completion Of Phase 1 Clinical Trial Of SAR 1118 Ophthalmic Solution SARcode Corporation, a privately-held biopharmaceutical company focused on developing small molecule LFA-1 antagonists to treat inflammatory diseases, today announced the completion of a Phase 1 study of the safety, tolerability, and pharmacokinetics of its lead molecule, SAR 1118 in
healthy human subjects.
Source: www.medicalnewstoday.comSomnus Therapeutics Completes Phase I Study Of Sleep Maintenance Drug Somnus Therapeutics, Inc., a private specialty pharmaceutical company developing a controlled-release sleep-maintenance therapy, and SkyePharma PLC (LSE:SKP) today announced the completion of the first Phase I study of SKP-1041. Under the terms of the licensing agreement between SkyePharma and Somnus, a US$1 million milestone payment is now payable to SkyePharma.
Source: www.medicalnewstoday.comEarly Stage, HER2-Positive Breast Cancer Patients At Increased Risk Of Recurrence Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.
Source: www.medicalnewstoday.comC.B. Fleet Voluntarily Recalls Its Fleet(R) Phospho-soda(R) Products After FDA Safety Alert Following the issuance of FDA's Safety Alert on Thursday stating that oral sodium phosphates bowel cleansing solutions should be available by
prescription only, C.B. Fleet Company immediately announced a voluntary recall of their over-the-counter products Fleet® Phospho-soda® and Fleet® Phospho-soda® EZ-Prep® Bowel Cleansing System.
Source: www.medicalnewstoday.comChromatin, Inc. Demonstrates Mini-Chromosome Performance Through 10 Generations Chromatin, Inc. presented their mini-chromosome research progress today at the American Seed Trade Association's 63rd Annual Corn and Sorghum Seed Research Conference in Chicago. The invited talk, entitled "Mini-chromosomes: The future of transgenic conversions" was presented by Shawn Carlson, Chromatin's Director of Crop Genetics.
Source: www.medicalnewstoday.comVIVUS Initiates Avanafil Phase 3 Trials For Males With Erectile Dysfunction VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced it has initiated the first of several pivotal phase 3 studies of avanafil, our investigational product for the treatment of erectile dysfunction (ED).
Source: www.medicalnewstoday.comSpectranetics Quick-Cross Extreme Product Line Receives FDA Clearance Spectranetics Corporation (NASDAQ:SPNC) today announced clearance from the Food and Drug Administration for the Quick-Cross Extreme™ product line, which represents an extension of its Quick-Cross support catheters. The FDA clearance follows the recent receipt of the CE Mark in Europe and approval to market these products in Canada.
Source: www.medicalnewstoday.comBlogs Comment On HHS Conscience Rule, Frozen Embryos, 'Mexico City' Policy The following summarizes selected women's
health-related blog entries. ~ "Repeal the Global Gag Rule," Rep. Nita Lowey (D-N.Y.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 PM
